Walleye Capital’s Protalix BioTherapeutics PLX Stock Holding History

Walleye Capital’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$46.2K	Buy	+19,839	New	+$42K	﹤0.01%	4207
2021 Q4	–	Sell	-220,089	Closed	-$293K	–	2264
2021 Q3	$293K	Sell	220,089 -126,450	-36%	-$192K	0.01%	1024
2021 Q2	$662K	Buy	+346,539	New	+$1.19M	0.02%	640
2020 Q3	–	Sell	-58,609	Closed	-$222K	–	940
2020 Q2	$222K	Buy	+58,609	New	+$200K	0.05%	404

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Walleye Capital's PLX Position: Q2 2026 in Review

Walleye Capital opened a new position in Protalix BioTherapeutics (PLX) in Q2 2026: 19,839 shares worth $46.2K. The stake represents ﹤0.01% of the portfolio and ranks #4207 among its holdings. This is a return to the name: Walleye Capital previously reported a position in PLX as recently as Q3 2021.

Walleye Capital first reported a position in PLX in Q2 2020 and has held it in 4 quarters since. The position peaked at $662K in Q2 2021. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Walleye Capital held 19,839 shares of Protalix BioTherapeutics worth $46.2K as of Q2 2026.
Protalix BioTherapeutics was a new Walleye Capital position in Q2 2026.
Protalix BioTherapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4207 holding.
Walleye Capital first reported a position in Protalix BioTherapeutics in Q2 2020 and has held it in 4 quarters since.
Walleye Capital's Protalix BioTherapeutics position peaked at $662K in Q2 2021.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.